| Nexsen Limited (NXN) ORDINARY FULLY PAID |
Health Care |
$22 |
Investor Presentation
|
8 Dec 2025 8:49AM |
$0.160 |
$0.240 |
risen by
50%
|
|
NXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Nexsen Limited is listed under ASX:NXN.
- The investor presentation is part of a non-deal roadshow in the United Kingdom.
- Presented by Managing Director Mark Muzzin and Executive Chairman Reece O’Connell.
- The document is authorized by the Board of Nexsen Limited.
- Reign Advisory handles corporate communications.
- Jane Morgan Management is responsible for media enquiries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beach Energy Limited (BPT) ORDINARY FULLY PAID |
Energy |
$2,065 |
First sales gas from the Waitsia Gas Plant
|
8 Dec 2025 8:46AM |
$1.170 |
$0.905 |
fallen by
22.65%
|
|
| Talius Group Limited (TAL) ORDINARY FULLY PAID |
Information Technology |
$22 |
Talius appoints new CEO & MD to bolster Leadership Team
|
8 Dec 2025 8:46AM |
$0.082 |
$0.063 |
fallen by
23.17%
|
|
TAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Talius Group Limited has appointed a new CEO and Managing Director.
- Mr. Howard will assume the role of CEO/MD starting February 2026.
- Mr. Russell will take on the role of Founder and Executive Director, Strategy and Growth.
- The new appointments are aimed at supporting the company's growth strategy.
- Mr. Howard's employment terms include a fixed remuneration of $350,000 per annum and performance-based incentives.
- Mr. Russell's new role includes a fixed remuneration of $275,000 per annum along with commission.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$530 |
Update - Notification of buy-back - ACL
|
8 Dec 2025 8:45AM |
$2.820 |
$2.840 |
risen by
0.71%
|
|
| Chalice Mining Limited (CHN) ORDINARY FULLY PAID |
Materials |
$525 |
Gonneville Project PFS - Teleconference and Webcast
|
8 Dec 2025 8:44AM |
$1.750 |
$1.345 |
fallen by
23.14%
|
|
| Novatti Group Limited (NOV) ORDINARY FULLY PAID |
Information Technology |
$11 |
AUDC raises $5m in its Pre-Series A round
|
8 Dec 2025 8:44AM |
$0.032 |
$0.018 |
fallen by
43.75%
|
|
NOV - Price-sensitive ASX Announcement
Full Release
Key Points
- AUDC raised $5m in Pre-Series A at A$0.80 per share.
- Novatti holds 20 million shares in AUDC, retaining a 45% interest.
- Novatti's interest in AUDC is now valued at $16m, up from $7m.
- The investment round was led by a large global institutional investor.
- AUDD became the first Australian Dollar stablecoin on Coinbase.
- Novatti's CEO, Mark Healy, highlighted the strategic value created from AUDD.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hansen Technologies Limited (HSN) ORDINARY FULLY PAID |
Information Technology |
$869 |
Notification of cessation of securities - HSN
|
8 Dec 2025 8:43AM |
$5.510 |
$4.250 |
fallen by
22.87%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,140 |
Update - Notification of buy-back - ZIP
|
8 Dec 2025 8:42AM |
$2.980 |
$2.520 |
fallen by
15.44%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$280 |
Update - Notification of buy-back - AMH
|
8 Dec 2025 8:42AM |
$1.040 |
$0.890 |
fallen by
14.42%
|
|
| National Storage REIT (NSR) ORDINARY FULLY PAID |
Real Estate |
- |
NSR enters into Scheme Implementation Deed
|
8 Dec 2025 8:40AM |
$2.730 |
$2.790 |
risen by
2.20%
|
|
| Ariadne Australia Limited (ARA) ORDINARY FULLY PAID |
Industrials |
$88 |
Update - Notification of buy-back - ARA
|
8 Dec 2025 8:40AM |
$0.500 |
$0.460 |
fallen by
8%
|
|
| Chalice Mining Limited (CHN) ORDINARY FULLY PAID |
Materials |
$525 |
Gonneville Project - Pre-Feasibility Study Presentation
|
8 Dec 2025 8:38AM |
$1.750 |
$1.345 |
fallen by
23.14%
|
|
| Paragon Care Limited (PGC) ORDINARY FULLY PAID |
Health Care |
$223 |
Change of Director's Interest Notice
|
8 Dec 2025 8:35AM |
$0.260 |
$0.135 |
fallen by
48.08%
|
|
| Ironbark Balanced Income Limited (IBC) ORDINARY FULLY PAID |
Financials |
$44 |
Update - Notification of buy-back - IBC
|
8 Dec 2025 8:35AM |
$0.435 |
$0.440 |
risen by
1.15%
|
|
| Altitude Minerals Ltd (ATT) ORDINARY FULLY PAID |
Materials |
$3 |
Drilling Commenced at Cu-Au Porphyry Drill Target
|
8 Dec 2025 8:35AM |
$0.024 |
$0.007 |
fallen by
70.83%
|
|
ATT - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling has commenced to test the T55 Cu-Au Porphyry Target in the interpreted NW extension of the Macquarie Arc, NSW.
- $80,000 NSW Government drilling grant awarded under the Critical Minerals and High-Tech Metals Exploration Program.
- Grant will contribute 40% of the cost for the 500m deep rotary mud and diamond core tail drill hole.
- Drilling expected to take two weeks with assays expected in early Q1, 2026.
- Program fully funded following a successful $2.5m placement.
- Altitude holds an Option to Earn-in agreement with project owner Nimrod Resources for up to a 75% interest in the Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$19 |
Canadian Govt Relations Firm to Accelerate Mavis Lake
|
8 Dec 2025 8:34AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Engagement of Pathway Group to support Mavis Lake Lithium Project.
- Pathway Group to provide strategic counsel and government engagement.
- Focus on unlocking government funding and strengthening stakeholder relationships.
- Mavis Lake positioned as a major lithium source for Canada and North America.
- Strategic location benefits include proximity to key markets and robust infrastructure.
- Strong government and community support for critical minerals development.
- Project advancement supported by Ontario's stable regulatory environment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tribeca Global Natural Resources Limited (TGF) ORDINARY FULLY PAID |
Financials |
$200 |
Update - Notification of buy-back - TGF
|
8 Dec 2025 8:34AM |
$2.110 |
$2.710 |
risen by
28.44%
|
|
| PPK Group Limited (PPK) ORDINARY FULLY PAID |
Materials |
$35 |
Final Director's Interest Notice - Marc Fenton
|
8 Dec 2025 8:33AM |
$0.385 |
$0.385 |
fallen by
0%
|
|
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$112 |
Update - Notification of buy-back - GEM
|
8 Dec 2025 8:33AM |
$0.705 |
$0.145 |
fallen by
79.43%
|
|
| Noviqtech Limited (NVQ) ORDINARY FULLY PAID |
Information Technology |
$16 |
NVQ, Eco-Markets Australia & Hashgraph- Reef Registry 2.0
|
8 Dec 2025 8:33AM |
$0.022 |
$0.039 |
risen by
77.27%
|
|
NVQ - Price-sensitive ASX Announcement
Full Release
Key Points
- NoviqTech partners with Eco-Markets Australia and The Hashgraph Group for Reef Credit Registry 2.0.
- The registry will leverage blockchain technology for transparency and scalability.
- Supported by a $160,000 grant from The Hashgraph Association.
- Phase 1 focuses on the delivery of a Minimum Viable Product (MVP) by mid-2026.
- Future phases aim to expand registry capabilities and support additional programs.
- The Hashgraph Group will oversee project coordination and scope management.
- NoviqTech's Carbon Central platform will be integrated into registry operations.
- Registry 2.0 aims to support a wide range of environmental credit programs beyond Reef Credits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evergold Minerals Limited (EG1) ORDINARY FULLY PAID |
Materials |
$12 |
New assay results confirm gold prospectivity at Bynoe, NT
|
8 Dec 2025 8:33AM |
$0.037 |
$0.027 |
fallen by
27.03%
|
|
EG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Re-assays from 2024 RC drilling confirmed gold mineralisation with notable intersections.
- Identified structural corridors are comparable to those hosting nearby multi-million-ounce deposits.
- Field work uncovered historical gold workings, reinforcing the project's gold potential.
- Auger re-assays are in progress to refine gold distribution understanding.
- A high-resolution geophysical campaign is planned for 2026.
- The Bynoe Project's gold focus is a strategic shift from initial lithium exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$552 |
Weekly NTA 05.12.2025
|
8 Dec 2025 8:33AM |
$3.170 |
$2.480 |
fallen by
21.77%
|
|
| DevEx Resources Limited (DEV) ORDINARY FULLY PAID |
Materials |
$153 |
Share Purchase Plan Opens
|
8 Dec 2025 8:33AM |
$0.200 |
$0.215 |
risen by
7.50%
|
|
| Jameson Resources Limited (JAL) ORDINARY FULLY PAID |
Materials |
$36 |
Share issue and cleansing notice
|
8 Dec 2025 8:33AM |
$0.079 |
$0.045 |
fallen by
43.04%
|
|
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$2 |
CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
|
8 Dec 2025 8:33AM |
$0.003 |
$0.035 |
risen by
1,066.67%
|
|
CHM - Price-sensitive ASX Announcement
Full Release
Key Points
- Orphan Drug Designation granted by FDA for CHM CDH17 in gastric cancer treatment.
- The designation offers tax credits, fee exemptions, and potential seven-year market exclusivity.
- Ongoing Phase 1/2 trial involves nine treated and ten enrolled patients.
- CHM CDH17 targets CDH17, linked to poor prognosis in common gastrointestinal tumors.
- Chimeric Therapeutics focuses on innovative cell therapies with multiple clinical programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.